Also known as LY3437943, retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors. Retatrutide is currently undergoing phase 3 trials and we expect it to be available as a prescription medication in 2029.
| mg | 10mg, 20mg, 30mg |
|---|
Be the first to review “Retatrutide”
Related products
Out of stock
Peptides
Price range: $59 through $129
Out of stock
Peptides
Price range: $39 through $89
Reviews
There are no reviews yet.